Sign in

Cough syrup samples of 54 pharma firms fail export quality test: Data

The data from the Central Drugs Standard Control Organisation (CDSCO) report was based on testing of samples in various states across the country

Updated on: Dec 5, 2023, 01:23:20 IST
Share
Share via
  • facebook
  • twitter
  • linkedin
  • whatsapp
Copy link
  • copy link

New Delhi: At least 6% cough syrup samples belonging to 54 Indian pharmaceutical manufacturers failed the mandatory quality test for export till October this year, according to government data.

(Representative Photo)
(Representative Photo)

The data from the Central Drugs Standard Control Organisation (CDSCO) report was based on testing of samples in various states across the country. Out of the 2,014 samples tested in government laboratories in states such as Maharashtra, Gujarat, Uttar Pradesh, and Union territory of Chandigarh, 128 (or 6%) failed the quality test and were found to be “not of standard quality” (NSQ), as per the government data.

The government laboratories designated for testing of samples, include Indian Pharmacopoeia Commission, Ghaziabad (Uttar Pradesh); Central Drugs Laboratory (CDL), Kolkata; Central Drug Testing Laboratory (CDTL), Chennai; CDTL, Mumbai; CDTL, Hyderabad; Regional Drugs Testing Laboratory (RDTL), Chandigarh; RDTL, Guwahati; and any NABL-accredited state drugs testing laboratory.

Also read- WHO issues substandard medicine alert in Iraq for India made cough syrup

According to the government data, of the 385 samples tested in the Gujarat lab, 51 were found to be NSQ, while 29 out of 502 samples failed the quality test in the Ghaziabad lab.

Earlier, the Union commerce ministry through an order in May this year had made it mandatory for cough syrup manufactures to get their stocks tested at a government lab before shipping for export.

The directive was issued after India-made cough syrups were allegedly linked to deaths of children in some countries. In December last year, Noida-based Marion Biotech’s cough syrup was linked to the death of 18 children in Uzbekistan. On October 5, 2022, World Health Organisation had issued a medical product alert over four cough syrups — Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup — manufactured and exported by Haryana-based Maiden Pharmaceuticals. The UN body had linked Maiden’s syrups to the death of 66 children in The Gambia.

  • Rhythma Kaul
    ABOUT THE AUTHOR
    Rhythma Kaul

    Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.Read More